FOLD David Michael Clark sells $282K worth of shares
Dec 18, 2025, 5:35 AM
0.00%
What does FOLD do
Amicus Therapeutics, a Philadelphia-based biotechnology company with 517 employees, went public in 2007 and markets Galafold for Fabry disease and Pombiliti + Opfolda for late-onset Pompe disease. Galafold stabilizes alpha-Gal A enzyme, while Pombiliti + Opfolda enhances enzyme uptake in relevant tissues.
David Michael Clark sold 25,643 shares of FOLD on 15 December at $11.00 per share, worth a total of $282K. They now own 271,332 FOLD shares, or a 9% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.